Pfizer extends tender offer for King
NEW YORK — A subsidiary of Pfizer has extended the expiration date of its tender offer to acquire all outstanding shares of common stock of King Pharmaceuticals.
Parker Tennessee’s tender offer now is scheduled to expire Jan. 21, as certain conditions to the tender offer wouldn’t have been satisfied by the previously scheduled expiration date — which was Dec. 17 — including the expiration or earlier termination of any waiting period under the Hart-Scott-Rodino Antitrust Improvements Act.
Other terms and conditions of the offer remain unchanged. Pfizer and King expected the deal to be completed by first quarter 2011.
Back in October, Pfizer announced it would acquire Bristol, Tenn.-based King for $3.6 billion, or $14.25 per share.
Biodel’s Steiner to retire, remains board member
DANBURY, Conn. — A drug maker specializing in the treatment of diabetes announced the retirement of its chief scientific officer.
Biodel this week said Solomon Steiner, who is a company co-founder, will remain on the company’s board of directors. Prior to holding his chief scientific officer position, Steiner was chairman, president and CEO of Biodel from its inception in late 2003 through March of this year, at which point Errol De Souza was appointed to be the company’s president and chief executive, and Charles Sanders was named board chairman.
"In 2003, I started Biodel with a vision of making a difference in patients’ lives," Steiner said. "Over the course of seven years, I have had the privilege of assembling a talented scientific team and working with them to create a portfolio of product candidates, which continues to grow. I am confident that with Errol De Souza’s leadership, this team will be able to bring these important innovations to market for the benefit of patients everywhere. I look forward to continuing to advise Biodel as a member of the board of directors."
Rite Aid’s new loyalty program a major bright spot in tough Q3
CAMP HILL, Pa. — What Rite Aid might wish for Christmas is accelerated results borne from its Wellness+ loyalty card program, because even as the chain lowered its guidance for fiscal 2011 sales, it’s that differentiated loyalty program that executives believe is going to buttress sales next year and beyond.
Based on its third-quarter results and its lower expectation for same-store sales in the fourth quarter, Rite Aid lowered its fiscal 2011 guidance for sales and adjusted EBITDA, and increased fiscal 2011 guidance for net loss. Sales now are expected to be between $25 billion and $25.2 billion, with same-store sales expected to range from a decrease of 1.5% to a decrease of 0.9%. Net loss is expected to fall between $655 million, or 74 cents per diluted share, and $525 million, or 60 cents per diluted share.
Even with the lowered guidance, Rite Aid was bullish regarding its Wellness+ program. “[Wellness+] helped fuel a significant turnaround in front-end sales,” John Standley, Rite Aid president and CEO, told analysts Thursday morning during the chain’s third-quarter conference call. “We continue to exceed our enrollment [projections] in Wellness+,” he said.
In the first eight months of the program, more than 29 million customers have opted into a loyalty program that successfully connects the pharmacy business with the front end. Through the first two weeks of December, 70% of front-end sales were connected to a loyal consumer, and 50% of pharmacy sales were transacted with a Wellness+ card. Excluding New York and New Jersey (two states that don’t allow loyalty programs to accumulate points for prescriptions filled), 64% of prescriptions were filled by patients enrolled in the Wellness+ program.
Total market basket of those Wellness+ customers is 50% higher than Rite Aid’s transient customers, versus 40% higher as of the last quarter, Standley said. And while much of the impact of Wellness+ to date has been connected to helping front-end sales, the program bodes well for the back end, too. “As Wellness+ matures, it will help us grow script counts,” Standley said. “Wellness+ retains and attracts good pharmacy customers.”
Other positive initiatives to come out of Rite Aid’s conference call with analysts included its focus on growing its flu vaccine business, its partnership with Supervalu on 10 Save-A-Lot/Rite Aid combination stores in Greenville, S.C., and the chain’s segmentation initiative, particularly among low-volume stores.
Rite Aid projected administering between 700,000 and 750,000 flu shots for the year. And while that’s down from the chain’s original estimates of more than 1 million shots (flu activity has been down versus the H1N1 pandemic last year), Rite Aid will have administered more shots this year than last, and 30% of those patients taking advantage of Rite Aid’s program are new customers. “This business will continue to grow in the future,” Standley said, especially as more Rite Aid pharmacists complete the chain’s immunization program and as awareness that these services are available at Rite Aid increases among the public.
The discount/limited grocery assortment concept in South Carolina is seeing 100% growth in comparable sales across the front end, reflecting an increase in the number of customers now walking through the doors. Standley told analysts that Rite Aid and Supervalu were discussing possibly expanding the program beyond South Carolina going forward. The low-volume segmentation stores, which feature some 9,000 fewer SKUs, a “Wall of Values” and a dollar section, have realized 10% growth in comparable sales.
Rite Aid reported revenues of $6.2 billion, a drop of 2.4% versus last year and a net loss of $79.1 million, or nine cents per diluted share, for the quarter ended Nov. 27. Rite Aid cited a slower start to the cough, cold and flu season, coupled with an increase in workers’ compensation and general liability self-insurance expense, as reasons behind the less-than-expected results. “While the lack of cough, cold and flu had a significant impact on our results, the good news is that our front-end sales began to turn around during the quarter, and our team continued to do a good job of controlling costs,” Standley said.
Same-store sales for the quarter decreased 1.3% over the prior 13-week period, with flat front-end sales and a 1.9% decrease in the pharmacy. Pharmacy sales included an approximate 242 basis point negative impact from new generic introductions, Rite Aid reported. The number of prescriptions filled in comparable stores decreased 1.7% over the prior-year period, negatively impacted 1.3% by the lower incidence of cough, cold and flu. Prescription sales accounted for 68.3% of total drug store sales and third-party prescription revenue was 96.2% of pharmacy sales.